Please assess the completion status of the following clinical trial:

Trial Title: Bioness® StimRouter™ Neuromodulation System for Chronic Pain Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults (≥ 22 years) suitable for an implanted electrode for pain relief.~2. Subjects who are able to give informed consent and to understand and comply with study requirements.~3. Subjects who have severe intractable chronic pain of peripheral nerve origin associated with post traumatic/post surgical neuralgia for ≥ 3 months (i.e., intractable to pain medication).~4. Subjects who are able to tolerate skin surface stimulation (TENS).~5. Subjects who have a worst chronic pain level in the last 24 hours ≥ 5/10 (on 0-10 NRS) where such pain is attributable to a lesion or disease of the somatosensory nervous system.~6. Subjects who are on a stable dose of pain medications for at least four weeks prior to screening and willing and able to maintain an equivalent dosage of their current pain medications from randomization to 3-month follow-up.~Exclusion Criteria:~1. Subjects who are not willing and able to maintain stable dosages of their pain medications from randomization to 3-month follow-up.~2. Subjects with a pain condition that could be confused with their peripheral neuropathic pain or that is more severe than their peripheral neuropathic pain.~3. Subjects who, for implantation in the trunk, have an implanted demand-type cardiac pacemaker or defibrillator.~4. Subjects who have a metal implant in the area for StimRouter implantation without Sponsor approval. Maintain a minimum separation distance of 6 inches (15 cm) between the StimRouter system and all other active implanted devices and metallic implants.~5. Subjects who require, or are likely to require, diathermy at the implant site.~6. Subjects who require, or are likely to require, therapeutic ultrasound at the implant site.~7. Subjects who have a cancerous lesion present near the target stimulation point or near to where the StimRouter user patch will adhere.~8. Subjects who are known or suspected to have a nickel allergy.~9. Subjects with bleeding disorders or active anticoagulation that cannot be stopped for a few days close to the time of the surgical procedure.~10. Subjects who decline to provide written consent or follow-up.~11. Subjects who are pregnant, plan on becoming pregnant, or are breastfeeding during the study period. Subjects who are female of child-bearing potential must have a negative pregnancy test at baseline visit and, if sexually active, must be using a medically acceptable method of contraception for the duration of the study participation.~12. Subjects who have an active systemic infection or are immunocompromised.~13. Subjects who have an active or existing skin disorder or irritation, which, at the physician's discretion, precludes the use of skin gel electrodes.~14. Subjects who currently require or are likely to require Magnetic Resonance Imaging (MRI) within the MRI exclusion zone: the entire StimRouter lead must be at least 50 cm from the center of the MR system's bore (the iso-center) and at least 16 cm outside of the MR coil measured from the edge of the MR coil.~15. Subjects who have a history of adverse reactions to local anesthetic (e.g., lidocaine).~16. Subjects who are participating in any other study that could affect the outcome of the StimRouter study, such as a spinal stimulation study, without Sponsor approval.~17. Subjects who are in litigation or who have pending or an active worker's compensation claim.~18. Subjects with less than one year of life expectancy.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- StimRouter - active stimulation (Type: EXPERIMENTAL): StimRouter- active electrical stimulation is applied transdermally to a targeted peripheral nerve. This is accomplished via a fully implanted StimRouter lead that receives energy from a rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes. The EPT receives radio frequency (RF) commands from a Patient Programmer. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer. Up to eight stimulation programs may be saved on a Patient Programmer for on-demand selection by the study patient.
- StimRouter - Control (Type: SHAM_COMPARATOR): StimRouter- Electrical stimulation is withheld from the targeted peripheral nerve after fully implanting the StimRouter lead. The rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes is placed for transdermal stimulation but no stimulation is delivered. The EPT which normally receives radio frequency (RF) commands from a Patient Programmer is not activated. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer such that no stimulation occurs in the Control Arm of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete